Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Biogen

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

Axios

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card

Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Axios

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Investors Business Daily

FDA’s approval of Biogen Alzheimer’s drug slammed in report

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

Tribune News Service

Probe: Alzheimer's drug approval 'rife with irregularities'

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

House report questions FDA’s approval of Alzheimer’s drug

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

Tribune News Service

House report questions FDA's approval of Alzheimer's drug - Roll Call

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Roll Call

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

Investors Business Daily

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation

Lots of breakthroughs, still no cure. Do new dementia drugs bring us any closer?

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The New Daily

Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The Conversation

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Al Jazeera

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Investors Business Daily

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

The New Daily

‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

WEKU

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Investors Business Daily

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors

Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

Axios

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

Investors Business Daily

Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback

Axsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback.

The Guardian - US

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

The Guardian - UK

‘This looks like the real deal’: are we inching closer to a treatment for Alzheimer’s?

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.